Tag: cancer biomarker market share

Uncover key drivers, emerging technologies, and competitive movements shaping the sleep disorder market from 2026–2035 with trusted insights from The Business Research Company

How much larger will the Cancer Biomarker Market be in 2030 compared with 2026?_x000D_

The cancer biomarker market has shown rapid expansion in recent years. It is projected to grow from $25.09 billion in 2025 to $29.07 billion by 2026, at a compound annual growth rate (CAGR) of 15.9%. This historical growth can be attributed to several factors including the rising global prevalence of cancer, breakthroughs in molecular biology research, increased funding for oncology research, the growing acceptance of biomarker-based diagnostics, and advancements in imaging and assay technologies._x000D_

_x000D_

The cancer biomarker market size is anticipated to experience substantial growth over the coming years, reaching $52.63 billion by 2030, exhibiting a compound annual growth rate (CAGR) of 16.0%. This expansion during the forecast period is driven by factors such as the increasing need for personalized oncology treatments, growing investments in precision medicine, the broadening of biomarker-driven drug development, the rising adoption of AI-based biomarker analysis, and a heightened emphasis on early-stage cancer screening. Key trends projected for this period involve the greater utilization of genetic and protein biomarkers, an uptick in the adoption of companion diagnostics, the expanding integration of omics technologies, the wider application of liquid biopsy techniques, and an intensified focus on early cancer detection._x000D_

_x000D_

#Access Your Free Sample Report for In-Depth Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp_x000D_

_x000D_

What Drivers Are Guiding Growth Patterns In The Cancer Biomarker Market?_x000D_

The increasing occurrence of cancer is a key factor boosting the expansion of the cancer biomarker market. The cancer incidence rate defines the count of newly diagnosed cancers for a particular location or kind within a specified population over a year, expressed as the number of cancers per 100,000 individuals susceptible. This growing frequency of cancer cases is prompting the extensive adoption of cancer biomarkers, given their utility in evaluating disease susceptibility, detecting hidden primary tumors, distinguishing between benign and malignant indicators, and differentiating various types of malignancy. These biomarkers are instrumental in the early identification, diagnosis, and ongoing monitoring of cancer by signaling the disease’s presence or advancement, which facilitates tailored treatments and enhances patient results. For example, in May 2024, a report released by the International Agency for Research on Cancer (IARC), a cancer research body situated in France, stated that around 20 million new cancer cases were recorded in 2022, leading to 9.7 million deaths. Furthermore, by 2050, more than 35 million new cancer cases are anticipated, marking a 77% surge relative to 2022. Consequently, the increasing occurrence of cancer is anticipated to fuel the expansion of the cancer biomarker market in the upcoming years._x000D_

_x000D_

How Is The Cancer Biomarker Market Divided Into Segments?_x000D_

The cancer biomarker market covered in this report is segmented – _x000D_

_x000D_

1) By Biomarker Type: Protein Biomarkers, Genetic Biomarkers, Other Biomarker Types_x000D_

2) By Profiling Technologies: Omics Technologies, Immunoassay, Bioinformatics, Cytogenetics_x000D_

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers_x000D_

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications_x000D_

_x000D_

Subsegments:_x000D_

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein_x000D_

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles_x000D_

3) By Other Biomarker Types: Epigenetic Biomarkers, Metabolomic Biomarkers_x000D_

_x000D_

Which Trends Are Guiding The Evolution Of The Cancer Biomarker Market?_x000D_

Major companies operating in the cancer biomarker market are concentrating on developing innovative solutions, such as AI-driven cancer biomarkers, to improve diagnostic precision and tailor treatment plans for patients. AI-powered cancer biomarkers refer to biological indicators of cancer that are identified and analyzed using artificial intelligence technologies. For instance, in September 2023, Ibex Medical Analytics, a US-based Ibex Medical Analytics, introduced Galen Breast HER2, an AI-powered solution designed to enhance the accuracy and reproducibility of HER2 scoring in breast cancer patients. This innovative platform assists pathologists by automatically detecting invasive tumor areas and quantifying HER2 expression based on the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system utilizes a novel computational pipeline to analyze immunohistochemistry (IHC)-stained slides, providing detailed visualizations of staining patterns and enabling pathologists to make informed treatment decisions._x000D_

_x000D_

Which Key Market Players Are Investing In Expansion And Innovation Within The Cancer Biomarker Market?_x000D_

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc. _x000D_

_x000D_

#Access The Complete Report For Deeper Market Insights:#_x000D_

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report_x000D_

_x000D_

Which Regions Are Poised For Strategic Growth In The Cancer Biomarker Market?_x000D_

North America was the largest region in the cancer biomaker market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa._x000D_

_x000D_

#Request Your Customized Cancer Biomarker Market Research Report for Competitive Advantage:#_x000D_

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp_x000D_

_x000D_

#Browse Through More Reports Similar to the Global Cancer Biomarker Market 2026, By The Business Research Company#_x000D_

_x000D_

Calcium Peroxide Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/calcium-peroxide-global-market-report_x000D_

_x000D_

Calcium Channel Blocker Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/calcium-channel-blocker-global-market-report_x000D_

_x000D_

Calcium Nitrate Global Market Report 2026_x000D_

https://www.thebusinessresearchcompany.com/report/calcium-nitrate-global-market-report_x000D_

_x000D_

#Get in touch with us:#_x000D_

_x000D_

The Business Research Company: https://www.thebusinessresearchcompany.com/_x000D_

Americas +1 310-496-7795_x000D_

Asia +44 7882 955267 & +91 8897263534_x000D_

Europe +44 7882 955267_x000D_

Email us at info@tbrc.info_x000D_

_x000D_

#Follow us on:#_x000D_

_x000D_

LinkedIn: https://in.linkedin.com/company/the-business-research-company_x000D_

Uncover key drivers, emerging technologies, and competitive movements shaping the cancer biomarker market from 2025–2034 with trusted insights from The Business Research Company

How Big Is The Cancer Biomarker Market Size Today And What Will Its Value Be At The End Of 2029?

The cancer biomarker market has experienced substantial growth in recent years. It is forecast to expand from $22.19 billion in 2024 to $25.09 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.1%. This historical expansion can be attributed to the shift towards personalized medicine, innovations in immunotherapy, the evolution of regulatory frameworks, collaborative research efforts, and a heightened focus on non-coding RNAs.

The cancer biomarker market is anticipated to experience substantial expansion over the upcoming years. This market is predicted to reach $45.33 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 15.9%. This expansion during the forecast timeframe is attributable to a move towards patient-focused diagnostics, the incorporation of biomarkers into clinical trials, the rise of multiplex biomarker panels, the investigation of non-coding RNAs, and the broader availability of biomarker tests. Key developments expected within this period encompass progress in genomics, personalized medicine strategies, liquid biopsy techniques, innovations in immunotherapy, and the adoption of artificial intelligence (AI).

Access A Free Sample Of The Report:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Key Drivers Are Powering Growth In The Cancer Biomarker Market?

The growing occurrence of cancer is a key factor propelling the expansion of the cancer biomarker market. This rate refers to the count of new cancer cases, specific to a site or type, observed within a particular population over a year, expressed as cancers per 100,000 individuals at risk. Consequently, the increased prevalence of cancer is fostering the extensive adoption of cancer biomarkers, which prove instrumental in evaluating disease risk, screening for hidden primary tumors, distinguishing between benign and malignant indicators, and differentiating various forms of malignancy. As an illustration, in January 2022, the American Cancer Society, a US-based health organization, published research indicating that the US is projected to see 609,360 cancer deaths and 1.9 million new cancer cases in 2022. This translates to approximately 1,670 fatalities daily. Consequently, the escalating occurrence of cancer is forecasted to boost the expansion of the cancer biomarker market in the forthcoming years.

Which Segment Categories Are Driving Maximum Growth In The Cancer Biomarker Market?

The cancer biomarkermarket covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

What Key Trends Are Driving Growth In The Cancer Biomarker Market?

Leading companies within the cancer biomarker market are focused on developing groundbreaking solutions, such as AI-driven cancer biomarkers, to improve diagnostic precision and personalize treatment approaches for patients. AI-powered cancer biomarkers are defined as biological indicators of cancer that are identified and analyzed using artificial intelligence technologies. As an illustration, in September 2023, Ibex Medical Analytics, a US-based firm, introduced Galen Breast HER2, an AI-powered solution crafted to elevate the accuracy and reproducibility of HER2 scoring in breast cancer patients. This innovative platform supports pathologists by automatically detecting invasive tumor regions and quantifying HER2 expression in line with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system utilizes a novel computational pipeline to analyze immunohistochemistry (IHC)-stained slides, delivering detailed visualizations of staining patterns and enabling pathologists to make informed treatment decisions.

Who Are The Leading Companies Driving The Cancer Biomarker Market?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Download The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Which Region Holds The Largest Share In The Cancer Biomarker Market Today?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Get A Report Customized For You Here:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

Browse Through More Reports Similar to the Global Cancer Biomarker Market 2025, By The Business Research Company

Pain Management Devices And Therapies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Isothermal Nucleic Acid Amplification Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

#What Is The Projected Market Size Of The Cancer Biomarker Market By 2029?

The market for cancer biomarkers has experienced considerable expansion lately, with projections indicating a rise from $22.19 billion in 2024 to $25.09 billion the following year, reflecting a 13.1% compound annual growth rate during this span; this upward trajectory during the past period is largely credited to the increasing adoption of tailored medical treatments, advancements in immunotherapies, changes in governmental regulations, joint research activities, and a growing emphasis on non-coding RNA studies.

Anticipation surrounds the cancer biomarker sector, projecting substantial expansion throughout the impending years, culminating in a market valuation of $45.33 billion by 2029, underpinned by a compound annual growth rate (CAGR) of 15.9%. This accelerated development throughout the projection timeframe stems from several key factors, notably the evolving emphasis on diagnostics tailored to individual patients, the incorporation of biomarkers into the rigors of clinical investigations, the proliferation of sophisticated panels featuring multiple biomarkers, ongoing research into non-coding RNA elements, and the successful market introduction of various biomarker assays. Key directional shifts observed during this period encompass significant progress in genomic technologies, the wider adoption of precision medicine strategies, the rising prominence of liquid biopsy techniques, advancements in immunotherapy modalities, and the increasing integration of artificial intelligence (AI) capabilities.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Industry Drivers Are Expected To Accelerate The Cancer Biomarker Market From 2025 To 2029?

The increasing prevalence of cancer is the primary factor fueling the expansion of the cancer biomarker sector. Cancer incidence is defined as the quantification of novel cancers of a particular type or location arising within a specified population over the course of one year, typically expressed as the count of cancers per 100,000 individuals susceptible to the disease. Escalating cancer cases necessitate the broader application of cancer biomarkers, given their utility in evaluating potential disease risk, detecting hidden malignant growths, distinguishing between non-cancerous and cancerous characteristics, or differentiating between various types of cancer. Illustratively, data released in January 2022 by the American Cancer Society, a healthcare authority based in the United States, projected 1.9 million new cancer diagnoses and 609,360 cancer-related fatalities across the US for that year, effectively equating to approximately 1,670 deaths daily. Consequently, the upward trend in cancer occurrences is anticipated to stimulate market growth for cancer biomarkers in the foreseeable future.

What Are The Emerging Segments Gaining Attention In The Cancer Biomarker Market?

The cancer biomarkermarket covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

What Long-Term Trends Will Shape The Future Growth Of The Cancer Biomarker Industry?

Leading entities within the cancer biomarker sector are concentrating their efforts on engineering novel offerings, specifically those integrating artificial intelligence for cancer diagnostics, aiming to elevate the precision of disease identification and tailor therapeutic strategies for individuals receiving care. AI-driven cancer biomarkers represent biological signals associated with malignancy that are uncovered and assessed employing sophisticated artificial intelligence methodologies. To illustrate, in the month of September in 2023, the United States firm, Ibex Medical Analytics, introduced Galen Breast HER2, an AI-enabled application developed to boost both the correctness and consistency in assigning HER2 scores for individuals diagnosed with breast cancer. This sophisticated system assists medical examiners by automatically pinpointing malignant tumor regions and measuring the level of HER2 expression, strictly adhering to the standards set forth in the 2018 ASCO/CAP guidelines. Employing a fresh computational sequence, the Galen Breast HER2 apparatus scrutinizes slides stained via immunohistochemistry (IHC), furnishing comprehensive visual representations of the staining characteristics which empowers pathologists to arrive at sound therapeutic choices.

Who Are The Top Performing Companies In The Cancer Biomarker Market In Recent Years?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

What Regional Growth Trends Are Shaping The Cancer Biomarker Market Outlook?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Cancer Biomarker Market Report:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

Browse Through More Reports Similar to the Global Cancer Biomarker Market 2025, By The Business Research Company

Pain Management Devices And Therapies Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/pain-management-devices-and-therapies-global-market-report

Metabolomics Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/metabolomics-global-market-report

Isothermal Nucleic Acid Amplification Technology Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

How Has The Cancer Biomarker Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size of cancer biomarkers has witnessed considerable expansion in recent years, growing from $22.19 billion in 2024 and projected to reach $25.09 billion in 2025. This significant increase at a compound annual growth rate (CAGR) of 13.1% can be correlated to various factors. They include the transition towards personalized medicine, the advent of immunotherapy innovations, the evolution of the regulatory framework, combined research initiatives, and an increased focus on non-coding RNAs.

In the upcoming years, the cancer biomarker market is forecasted to experience swift expansion, escalating up to $45.33 billion by 2029, with a CAGR of 15.9%. The expected growth during the forecast period can be associated with the transition towards patient-oriented diagnostics, the inclusion of biomarkers in clinical studies, the development of multi-biomarker panels, exploration of non-coding RNAs and the bringing of biomarker tests to market. The period also anticipates advancements in sectors such as genomics, precision medicine strategies, liquid biopsies, advances in immunotherapy, and integration of artificial intelligence.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theCancer Biomarker Market?

The increasing occurrence of cancer is propelling the expansion of the cancer biomarker market. The cancer frequency rate refers to the amount of new cancers of a particular location/type that arise in a particular population within a certain year, it is presented as cancers per 100,000 individuals at risk. The rising prevalence of cancer is promoting the extensive utilization of cancer biomarkers given their importance in determining disease risk, screening for hidden primary tumors, identifying benign from malignant signs, or differentiating between various forms of malignancy. For example, in January 2022, the American Cancer Society, a health organization based in the US, published research indicating an anticipation of 609,360 cancer deaths and 1.9 million new instances of cancer in 2022. This equates to approximately 1,670 fatalities on a daily basis. Consequently, the increasing occurrence of cancer will likely accelerate the expansion of the cancer biomarker market in the forthcoming years.

Which Segments in the Cancer Biomarker Offer the Most Growth?

The cancer biomarkermarket covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

What Are the Fastest-Growing Geographies in the #How Are Key Drivers in the Industry Acting as Catalysts for the Growth of theCancer Biomarker Market?# Market?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Current Market Growth and Trends in the Cancer Biomarker Industry?

Key market players in the cancer biomarker sector are concentrating on the creation of inventive solutions, such as AI-enabled cancer biomarkers, to improve diagnostic precision and create tailored treatment strategies for individuals. AI-powered cancer biomarkers denote biological cancer signals that are detected and investigated using artificial intelligence mechanisms. For example, in September 2023, Ibex Medical Analytics, an American company, introduced Galen Breast HER2, an AI-supported solution engineered to boost the reliability and repeatability of HER2 grading in breast cancer patients. This groundbreaking platform supports pathologists by auto-detecting invasive tumor regions and quantifying HER2 expression in alignment with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system employs an innovative computational process to scrutinize immunohistochemistry (IHC)-stained slides, offering detailed imagery of staining patterns and empowering pathologists to make insightful treatment choices.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

What Are the Key Elements That Define the Cancer Biomarker Market?

A cancer biomarker refers to a biological molecule present in the blood, tissues, or other bodily fluids, that indicates the presence of normal or abnormal activity, as well as a condition or disease. Cancer biomarkers are used to characterize alterations in the tumor.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8492

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Europe +44 7882 955267

Asia & Others +44 7882 955267 & +91 8897263534

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Cancer Biomarker Market?

The market size of cancer biomarkers has experienced significant growth in the past few years. Its size is projected to increase from $22.19 billion in 2024 to $25.28 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.9%. The historic period’s growth has been influenced by a turn toward personalized medicine, advancements in immunotherapy, changes in regulatory frameworks, a boost in cooperative research efforts, and a focus on non-coding RNAs.

What Growth Rate Is Forecasted for the Cancer Biomarker Market by 2029?

The market size for cancer biomarkers is anticipated to undergo significant expansion in the upcoming years, with an expected valuation of $45.88 billion in 2029 and a compound annual growth rate (CAGR) of 16.1%. The predicted growth in this period can be credited to a transition towards diagnostics that focus on individual patients, the implementation of biomarkers in clinical studies, the development of multiplex biomarker panels, study into non-coding RNAs, and the commercialization of biomarker tests. Notable trends in the forecasted period comprise breakthroughs in the field of genomics, precision medicine strategies, liquid biopsy technologies, advancements in immunotherapy, and the integration of artificial intelligence (AI).

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Key Companies Are Shaping the Future of the Cancer Biomarker Market?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Which Factors Are Driving Demand in the Cancer Biomarker Industry?

The cancer biomarker market is expanding due to the escalating rates of cancer occurrences. Defined as the number of new cancer cases of a certain type, occurring in a specified population in a year, the cancer incidence rate is typically expressed as cancers per 100,000 people at risk. Because of the ability of cancer biomarkers to gauge disease risk, differentiate between benign and malignant symptoms, or distinguish one kind of cancer from another, their use is becoming more prevalent. For example, as per the research published by the American Cancer Society in January 2022, it is predicted that there will be 609,360 cancer-related deaths and around 1.9 million new cases of cancer in the U.S in 2022. This amounts to almost 1,670 deaths each day. Consequently, the growth of the cancer biomarker market is predicted to surge in response to the increasing presence of cancer in the future.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

How Is the Cancer Biomarker Market Segmented by Several Divisions?

The cancer biomarker market covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

What are the Emerging Market Trends Driving the Growth of the Cancer Biomarker Industry?

Prominent businesses in the cancer biomarker industry are concentrating on producing novel solutions like AI-enabled cancer biomarkers, with the aim of improving diagnosis precision and customizing treatment pathways for patients. AI-driven cancer biomarkers are biological markers of cancer that are discerned and examined using artificial intelligence tools. For instance, in September 2023, the American firm Ibex Medical Analytics rolled out Galen Breast HER2, which is an AI-based solution to increase HER2 scoring accuracy and consistency in patients with breast cancer. This pioneering platform assists pathologists by autonomously identifying invasive tumor locations and measuring HER2 expression in congruence with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 solution employs an innovative computational process for analyzing immunohistochemistry (IHC)-dyed slides, giving comprehensive visualizations of staining formations hence enabling pathologists to make knowledgeable treatment choices.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Which Regions Are Driving Growth in the Cancer Biomarker Market?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8492

This Report Delivers Insight On:

1. How big is the cancer biomarker market, and how is it changing globally?

2. Who are the major companies in the cancer biomarker market, and how are they performing?

3. What are the key opportunities and risks in the cancer biomarker market right now?

4. Which products or customer segments are growing the most in the cancer biomarker market?

5. What factors are helping or slowing down the growth of the cancer biomarker market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 2071930708

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Cancer Biomarker Market?

The market size of cancer biomarkers has experienced significant growth in the past few years. Its size is projected to increase from $22.19 billion in 2024 to $25.28 billion in 2025, demonstrating a compound annual growth rate (CAGR) of 13.9%. The historic period’s growth has been influenced by a turn toward personalized medicine, advancements in immunotherapy, changes in regulatory frameworks, a boost in cooperative research efforts, and a focus on non-coding RNAs.

What Growth Rate Is Forecasted for the Cancer Biomarker Market by 2029?

The market size for cancer biomarkers is anticipated to undergo significant expansion in the upcoming years, with an expected valuation of $45.88 billion in 2029 and a compound annual growth rate (CAGR) of 16.1%. The predicted growth in this period can be credited to a transition towards diagnostics that focus on individual patients, the implementation of biomarkers in clinical studies, the development of multiplex biomarker panels, study into non-coding RNAs, and the commercialization of biomarker tests. Notable trends in the forecasted period comprise breakthroughs in the field of genomics, precision medicine strategies, liquid biopsy technologies, advancements in immunotherapy, and the integration of artificial intelligence (AI).

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Key Companies Are Shaping the Future of the Cancer Biomarker Market?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Which Factors Are Driving Demand in the Cancer Biomarker Industry?

The cancer biomarker market is expanding due to the escalating rates of cancer occurrences. Defined as the number of new cancer cases of a certain type, occurring in a specified population in a year, the cancer incidence rate is typically expressed as cancers per 100,000 people at risk. Because of the ability of cancer biomarkers to gauge disease risk, differentiate between benign and malignant symptoms, or distinguish one kind of cancer from another, their use is becoming more prevalent. For example, as per the research published by the American Cancer Society in January 2022, it is predicted that there will be 609,360 cancer-related deaths and around 1.9 million new cases of cancer in the U.S in 2022. This amounts to almost 1,670 deaths each day. Consequently, the growth of the cancer biomarker market is predicted to surge in response to the increasing presence of cancer in the future.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

How Is the Cancer Biomarker Market Segmented by Several Divisions?

The cancer biomarker market covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

What are the Emerging Market Trends Driving the Growth of the Cancer Biomarker Industry?

Prominent businesses in the cancer biomarker industry are concentrating on producing novel solutions like AI-enabled cancer biomarkers, with the aim of improving diagnosis precision and customizing treatment pathways for patients. AI-driven cancer biomarkers are biological markers of cancer that are discerned and examined using artificial intelligence tools. For instance, in September 2023, the American firm Ibex Medical Analytics rolled out Galen Breast HER2, which is an AI-based solution to increase HER2 scoring accuracy and consistency in patients with breast cancer. This pioneering platform assists pathologists by autonomously identifying invasive tumor locations and measuring HER2 expression in congruence with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 solution employs an innovative computational process for analyzing immunohistochemistry (IHC)-dyed slides, giving comprehensive visualizations of staining formations hence enabling pathologists to make knowledgeable treatment choices.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

Which Regions Are Driving Growth in the Cancer Biomarker Market?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8492

This Report Delivers Insight On:

1. How big is the cancer biomarker market, and how is it changing globally?

2. Who are the major companies in the cancer biomarker market, and how are they performing?

3. What are the key opportunities and risks in the cancer biomarker market right now?

4. Which products or customer segments are growing the most in the cancer biomarker market?

5. What factors are helping or slowing down the growth of the cancer biomarker market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Discover trends, market shifts, and competitive outlooks for the cancer biomarker industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

What Is the Estimated Market Size of the Cancer Biomarker Market In 2029?

In recent times, the size of the cancer biomarker market has witnessed significant expansion. Predictions indicate that it will develop from $22.19 billion in 2024 to $25.28 billion in 2025, achieving a compound annual growth rate (CAGR) of 13.9%. The growth observed in the historic period is a reflection of factors such as the transition towards personalized medicine, advancements in immunotherapy, evolution of regulatory frameworks, concerted research initiatives, and an emphasis on non-coding RNAs.

In the coming years, the cancer biomarker market size is anticipated to experience fast-paced growth, with projections estimating it to reach $45.88 billion by 2029, growing at a compound annual growth rate (CAGR) of 16.1%. Factors contributing to this growth during the forecast period include a shift towards patient-centered diagnostic approaches, inclusion of biomarkers in clinical trials, the development of multiplex biomarker panels, exploration of non-coding RNAs, and the gradual commercialization of biomarker tests. Trends expected to shape the market during the forecast period include advancements in genomics, precision medicine strategies, the utilization of liquid biopsies, progression in immunotherapy, and the incorporation of artificial intelligence (AI).

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

Which Factors and External Forces Are Driving Demand in the Cancer Biomarker Market?

The cancer biomarker market’s progress is propelled by the escalating prevalence of cancer. The incidence rate of cancer refers to the number of newly diagnosed cancers, specific to a certain part or type, in a particular population over a specific year, expressed as cases per 100,000 people at risk. The surging prevalence of cancer is promoting the extensive use of cancer biomarkers due to their ability to evaluate disease risk, screen for hidden primary tumors, distinguish non-cancerous from cancerous symptoms, or differentiate various types of malignancies. For instance, research released by the American Cancer Society, a US-based health entity, in January 2022 showed that the US is estimating about 609,360 cancer-related deaths and roughly 1.9 million fresh cancer diagnoses in 2022, which equates to nearly 1,670 deaths daily. Consequently, the surging prevalence of cancer is projected to stimulate the progress of the cancer biomarker market in the forthcoming years.

Which Segments in the Cancer Biomarker Offer the Most Growth?

The cancer biomarker market covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smp

What Are the Fastest-Growing Geographies in the Cancer Biomarker Market?

North America was the largest region in the cancer biomaker market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer biomarker market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Which Cutting-Edge Market Trends Are Expected to Drive theCancer Biomarker Market’s Growth?

The leading firms in the cancer biomarker market are concentrating on the creation of innovative solutions such as cancer biomarkers powered by artificial intelligence. These are biological markers of cancer which are detected and analyzed using AI technologies to increase diagnostic precision and provide personalized treatment plans for patients. For example, in September 2023, a US-based company called Ibex Medical Analytics introduced Galen Breast HER2, a solution driven by AI that is meant to improve the reliability and accuracy of HER2 scoring in individuals with breast cancer. The new platform assists pathologists by identifying invasive tumor areas automatically and calculating the expression of HER2 according to the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system employs a unique computational pipeline to assess immunohistochemistry (IHC)-stained slides, offering comprehensive visualizations of staining patterns. This allows pathologists to make well-informed decisions on treatment.

View the full report here:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

What Are the Key Elements That Define the Cancer Biomarker Market?

A cancer biomarker refers to a biological molecule present in the blood, tissues, or other bodily fluids, that indicates the presence of normal or abnormal activity, as well as a condition or disease. Cancer biomarkers are used to characterize alterations in the tumor.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8492

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

2025 Market Reports Update: Market Size Forecasts to 2034, Key Trends, Leading Players, and Top Regions – Get Ahead of the Competition Today!

What Drivers Are Shaping the Growth and Development of theCancer Biomarker Market?

The upward trend of cancer occurrences is fueling the expansion of the cancer biomarker industry. Defined as the quantity of new cancer cases of a specific location or type seen in a certain population over a year, the cancer incidence rate is shown as occurrences of cancer per 100,000 individuals at risk. The surge in cancer incidence rates is triggering a rise in the use of cancer biomarkers as they help calculate the risk of disease, screen for undisclosed primary tumors, differentiate benign conditions from malignant ones, or separate one type of malignancy from another. For example, research released by the American Cancer Society, a health organization based in the US, in January 2022 indicated the expectation of 609,360 cancer-related deaths and 1.9 million new cancer cases in the US in 2022. This translates to roughly 1,670 deaths per day. As a result, the escalating incidence of cancer is anticipated to stimulate the development of the cancer biomarker industry in the upcoming years.

Get Your Free Sample Report Now – Explore Exclusive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=8492&type=smp

How Will the Growth Rate of theCancer Biomarker Market Impact Industry Trends by 2034?

The expansion of the cancer biomarker market has been quick and steady in the past few years. Currently valued at $22.19 billion in 2024, it is projected to reach $25.28 billion by 2025, reflecting a compounded annual growth rate (CAGR) of 13.9%. Factors such as the drive towards personalized treatments, advancements in immunotherapy, developments in regulatory guidelines, cooperation in research initiatives, and a focus on non-coding RNAs have contributed to the growth during the historic period.

The size of the cancer biomarker market is predicted to experience swift expansion in the coming years, reaching $45.88 billion by 2029 with a compound annual growth rate (CAGR) of 16.1%. This expansion during the predicted period can be ascribed to factors such as the transition to patient-focused diagnostics, incorporation of biomarkers into clinical trials, the advent of multiplex biomarker panels, studies on non-coding RNAs and the monetization of biomarker tests. The key trends in the forecast period are progress in genomics, applications of precision medicine, adoption of liquid biopsies, innovations in immunotherapy, and the insertion of artificial intelligence (ai).

You can Directly Purchase the Report Here:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=8492

Which Cutting-Edge Market Trends Are Expected to Drive theCancer Biomarker Market’s Growth?

Leading firms in the cancer biomarker sector are concentrating on creating innovative solutions, such as cancer biomarkers powered by artificial intelligence, in an effort to improve diagnostic precision and personalize care plans for patients. Cancer biomarkers powered by artificial intelligence are biological markers of cancer that are identified and analyzed through the use of AI technologies. For example, in September 2023, the US-based company, Ibex Medical Analytics, introduced Galen Breast HER2, an AI-driven solution specifically designed to boost the precision and consistency of HER2 scoring in breast cancer patients. This ground-breaking platform supports pathologists by autonomously identifying invasive tumor areas and quantifying HER2 expression in accordance with the 2018 ASCO/CAP guidelines. The Galen Breast HER2 system employs a unique computational pipeline to analyze immunohistochemistry (IHC)-stained slides, offering detailed visualizations of staining patterns and equipping pathologists with the necessary information to make knowledgeable treatment choices.

What Are the Leading Market Players Impacting theCancer Biomarker Market’s Growth Trend?

Major companies operating in the cancer biomarker market are F. Hoffmann-La Roche AG, Thermo Fisher Scientific Inc., QIAGEN NV, Illumina Inc., Bio-Rad Laboratories Inc., Abbott Laboratories, bioMérieux SA, Becton Dickinson and Company, Merck & Co. Inc., Bristol-Myers Squibb Company, PerkinElmer Inc., Siemens AG, Exact Sciences Corporation, Novartis AG, Agilent Technologies Inc., Hologic Inc., Myriad Genetics Inc., Foundation Medicine Inc., Guardant Health Inc., Natera Inc., Sysmex Corporation, Biocartis Group NV, NanoString Technologies Inc., Veracyte Inc., Epic Sciences Inc., Cynvenio Biosystems Inc., Genomic Health Inc., Oncocyte Corporation, Exosome Diagnostics Inc., Grail Inc.

Order Your Report Now For A Swift Delivery:

https://www.thebusinessresearchcompany.com/report/cancer-biomarker-global-market-report

How Are the Key Segments of the Cancer Biomarker Market Driving Opportunities and Innovations?

The cancer biomarker market covered in this report is segmented –

1) By Biomarkers Type: Protein Biomarkers, Genetic Biomarkers, Other Cancer Biomarkers

2) By Profiling Technologies: Omics Technologies, Imaging Technologies, Immunoassay, Bioinformatics, Cytogenetics

3) By Cancer Type: Breast Cancer, Lung Cancer, Colorectal Cancer, Prostate Cancer, Thyroid Cancer, Kidney Cancer, Other Cancers

4) By Application: Diagnostics, Research And Development, Prognostics, Risk Assessment, Other Applications

Subsegments:

1) By Protein Biomarkers: Tumor-Specific Antigens, Circulating Tumor Protein

2) By Genetic Biomarkers: DNA Mutations, RNA Expression Profiles

3) By Other Cancer Biomarkers: Epigenetic Biomarkers, Metabolomic Biomarkers

Gain Exclusive Market Insights—Customize Your Research Report Today for Fast Delivery!

https://www.thebusinessresearchcompany.com/customise?id=8492&type=smpGlobal Cancer Biomarker Market, Global Cancer Biomarker Market Report, Global Cancer Biomarker Market Trends, Global Cancer Biomarker Market Size

Browse Through More Reports Similar to the Gobal Cancer Biomarker Maret 2025, By The Business Research Company:

Lung Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/lung-cancer-drugs-global-market-report

Skin Cancer Drugs Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/skin-cancer-drugs-global-market-report

Isothermal Nucleic Acid Amplification Technology (INAAT) Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/isothermal-nucleic-acid-amplification-technology-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: